Identification of HMGCR as the anticancer target of physapubenolide against melanoma cells by in silico target prediction.

Abstract

Physapubenolide (PB), a withanolide-type compound extracted from the traditional herb Physalis minima L., has been demonstrated to exert remarkable cytotoxicity against cancer cells; however, its molecular mechanisms are still unclear. In this study, we demonstrated that PB inhibited cell proliferation and migration in melanoma cells by inducing cell apoptosis. The anticancer activity of PB was further verified in a melanoma xenograft model. To explore the mechanism underlying the anticancer effects of PB, we carried out an in silico target prediction study, which combined three approaches (chemical similarity searching, quantitative structure-activity relationship (QSAR), and molecular docking) to identify the targets of PB, and found that PB likely targets 3-hydroxy-methylglutaryl CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate pathway, which promotes cancer cell proliferation, migration, and metastasis. We further demonstrated that PB interacted with HMGCR, decreased its protein expression and inhibited the HMGCR/YAP pathway in melanoma cells. In addition, we found that PB could restore vemurafenib sensitivity in vemurafenib-resistant A-375 cells, which was correlated with the downregulation of HMGCR. In conclusion, we demonstrate that PB elicits anticancer action and enhances sensitivity to vemurafenib by targeting HMGCR.

• Authors: Hai-Yan Wang, Pian Yu, Xi-Sha Chen, Hui Wei, Shi-Jie Cao, Meng Zhang, Yi Zhang, Yong-Guang Tao, Dong-Sheng Cao, Feng Qiu, Yan Cheng
• Journal: Acta pharmacologica Sinica (Acta Pharmacol Sin) Vol. 43 Issue 6 Pg. 1594-1604 (Jun 2022) ISSN: 1745-7254 [Electronic] United States
• PMID: 34588618 (Publication Type: Journal Article)
• Copyright: © 2021. The Author(s).

Chemical References

• Withanolides
• physapubenolide
• Vemurafenib
• HMGCR protein, human
• Hydroxymethylglutaryl CoA Reductases

Topics

• Humans
• Hydroxymethylglutaryl CoA Reductases (metabolism)
• Melanoma (drug therapy)
• Molecular Docking Simulation
• Vemurafenib
• Withanolides (pharmacology)